European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPE6 March 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
MPE member spotlight: Fundacja Carita´s European Forum of Haemato-Oncological PatientsMPE, News6 February 2025
Register for MPE´s European Young Myeloma Patients Group webinar on myeloma and physical fitnessMPE, Myeloma, News5 February 2025
